8-K current report · filed Nov 12, 2026

Cardiff Oncology, Inc. (CRDF) 8-K Current Report: November 12, 2026

Item 2.02Item EX-99.1CRDF overview

Short answer

Cardiff Oncology, Inc. (CRDF) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 business update and financial results announced for quarter ended September 30, 2026.

Cardiff Oncology, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 2026 business update and financial results announced for quarter ended September 30, 2026
  • Full operating and financial details contained in Exhibit 99.1, Cardiff Oncology’s accompanying press release

Item EX-99.1 · Exhibit EX-99.1

  • Phase 2 efficacy signal strengthening: median PFS not reached at 30 mg onvansertib plus FOLFIRI/bev versus approximately 11 months for combined SoC arms
  • All remaining patients in the proposed Phase 3 regimen exceeded 21 months on treatment, with longest duration over 29 months
  • Registrational Phase 3 trial preparation underway, with potential first-line RAS-mutated mCRC launch in Q1 2027
  • Cash, equivalents and short-term investments $33.8M, funding projected through Q3 2027 at current spending plans
  • Nine-month net loss $30.4M versus $38.6M, while operating cash use rose to $33.9M from $31.9M

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Cardiff Oncology, Inc. 8-K filings

Get the next CRDF 8-K as it lands

Follow CRDF for push alerts, or ask the research agent what this filing means.